SonoThera's non-viral gene therapy approach wins Endpoints 11
26 September 2026 · filed under 19341bc1d9b2
SonoThera, a San Francisco-based biotechnology company, has been named a winner of Endpoints 11 for its non-viral approach to gene therapy delivery, according to Endpoints News.
The company is led by CEO Kenneth Greenberg and CSO Steve Feinstein. Endpoints News reports SonoThera has raised $186 million in total funding to date. Its investor roster includes Vida Ventures, ARCH Venture Partners, Illumina Ventures, Leaps by Bayer, Johnson & Johnson Innovation, and Eli Lilly, among others named in the report.
Endpoints News frames the company’s work around addressing limitations associated with viral vectors, which have long served as the standard delivery mechanism for gene therapies. Non-viral delivery methods, if successful, could expand the pool of patients and conditions eligible for gene therapy treatment, an outcome the outlet’s editors cite as the basis for including SonoThera among this year’s Endpoints 11 selections.
The Endpoints 11 designation is presented annually by Endpoints News to highlight companies the publication’s editors judge to be notable within the biotechnology sector. The report does not specify further details of SonoThera’s platform mechanics beyond its non-viral classification, nor does it list clinical trial data or regulatory status for any therapeutic candidates.
Endpoints News published the item on September 25, 2026.